Category: Research

GLP-1 Medications and Muscle Mass: Preserving Lean Tissue During Weight Loss

When losing significant weight on GLP-1 medicines, between 20% and 40% of total mass lost is lean tissue. We examine clinical trial DEXA findings and evidence-based protocols to preserve skeletal muscle.
CagriSema: Dual Amylin and GLP-1 Agonism in Clinical Trials

CagriSema combines the long-acting amylin analogue cagrilintide with semaglutide. Here is what Phase 3 REDEFINE 1 trial data demonstrate regarding its dual mechanism, 22.7% weight loss efficacy and current FDA NDA review.
Orforglipron (Foundayo): Clinical Evidence, Phase 3 Trials and FDA Approval

Approved by the US FDA on 1 April 2026 as Foundayo for chronic weight management, orforglipron is the first daily non-peptide oral GLP-1 receptor agonist taken without food or water restrictions. We examine its Phase 3 trial data, mechanisms and regulatory status.
Mysimba (Naltrexone/Bupropion): Mechanism, Evidence and Safety Profile

Mysimba combines naltrexone and bupropion to target hypothalamic hunger and mesolimbic reward circuits. Here is the evidence on its mechanism, weight loss outcomes from the COR trials, titration and contraindications.
Metformin for Weight Loss and Insulin Sensitivity: What the Evidence Shows

Metformin is the global first-line foundation for type 2 diabetes. We examine what clinical trials, including the 15-year Diabetes Prevention Program, prove regarding its modest, sustainable weight-loss effects and metabolic benefits.
Bremelanotide (PT-141): Central Melanocortin Agonism for Hypoactive Sexual Desire

Bremelanotide (PT-141) is a synthetic cyclic heptapeptide that acts centrally on hypothalamic melanocortin receptors to stimulate sexual desire. Here is what FDA approval data, the RECONNECT trials and research literature demonstrate.
Rapamycin (Sirolimus) for Longevity: mTOR Inhibition, Human Evidence and Safety

Rapamycin is the most robust pharmacological lifespan-extending compound in preclinical biology. We examine how mTOR inhibition works, the NIA Interventions Testing Program data, human trial evidence and safety risks.
NAD+ Precursors and Infusions: Cellular Biology, Oral NMN/NR vs IV NAD+

Nicotinamide adenine dinucleotide (NAD+) declines with age. We evaluate the cellular biology of the NAD+ salvage pathway, comparing oral precursors (NR, NMN) to intravenous infusions and reviewing human evidence.
TB-500 (Thymosin Beta-4 Fragment): Cellular Mechanisms and Tissue Repair Data

TB-500 is a synthetic peptide based on the active domain of Thymosin Beta-4. We examine how actin sequestration regulates cell migration, preclinical tissue repair data, anti-doping bans and research status.
GHK-Cu Copper Peptide: Evidence for Skin Remodelling and Wound Repair

GHK-Cu is a naturally occurring copper-binding tripeptide that regulates extracellular matrix remodelling and gene expression. We review the evidence behind its collagen-stimulating, wound-healing and dermatological properties.